Trials / Active Not Recruiting
Active Not RecruitingNCT06650007
the Efficacy and Safety of HRS9531 Injection in Subjects With Type 2 Diabetes， Inadequately Controlled With Diet and Exercise Alone
A Multicenter, Randomized, Double-blind, Placebo- Parallel Controlled, Phase III Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Type 2 Diabetes， Inadequately Controlled With Diet and Exercise Alone
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 218 (actual)
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to evaluate the effectiveness of HRS9531 compared to placebo in controlling blood glucose levels after 24 weeks of treatment
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HRS9531 Injection | HRS9531 Injection |
| DRUG | HRS9531 Placebo Injection | HRS9531 Placebo Injection |
Timeline
- Start date
- 2024-11-08
- Primary completion
- 2025-05-14
- Completion
- 2026-07-01
- First posted
- 2024-10-21
- Last updated
- 2025-06-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06650007. Inclusion in this directory is not an endorsement.